This research demonstrates an interpretable QSAR model achieving 83.67% accuracy in predicting VEGFR-2 inhibitors, implying enhanced drug discovery potential.
Cancer remains a major global health burden, with angiogenesis playing a central role in tumor growth and progression. Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is a key mediator of angiogenesis and an attractive therapeutic target, but existing inhibitors are limited by reduced efficacy, toxicity, and resistance, creating a need for more effective predictive models in drug discovery. In this study, an interpretable machine learning based QSAR approach was developed using a curated dataset of 10,221 VEGFR-2 inhibitors from ChEMBL represented by 164 molecular descriptors. Four algorithms, kNN, AdaBoost, Random Forest, and XGBoost, were compared, and XGBoost achieved the best results with an accuracy of 83.67 percent, sensitivity of 91.38 percent, specificity of 71.73 percent, F1-score of 87.17 percent, and AUC of 0.9009. Model interpretation with LIME identified molecular descriptors related to hydrogen bonding, electrostatics, and lipophilicity as key contributors to activity. These results indicate that interpretable ensemble models can combine strong predictive performance with mechanistic insights, supporting rational design and optimization of novel VEGFR-2 inhibitors for anticancer therapy.
No takes yet. Share an insight, caveat, or question.
Noviandy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: